# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, a...
Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid...
Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:AMPH) with a Hold.
JP Morgan analyst Ekaterina Knyazkova initiates coverage on Amphastar Pharma (NASDAQ:AMPH) with a Overweight rating and anno...
Amphastar Pharma (NASDAQ:AMPH) reported quarterly earnings of $0.88 per share which missed the analyst consensus estimate of $0...
Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would back Moderna, Inc. (NASDAQ: MRNA) here.
B of A Securities analyst Jason Gerberry initiates coverage on Amphastar Pharma (NASDAQ:AMPH) with a Neutral rating and anno...